About Michael Kelly
Michael Kelly is a director at Prime Medicine.
Form D filings name Michael Kelly as a director at Chroma Medicine.
Michael Kelly reports to the SEC as a director of 6 public companies, including Neogenomics (NEO), DMC Global (BOOM) and Amicus Therapeutics (FOLD).
Michael Kelly first appears on SEC filings in 2019.
Experience
This experience comes from SEC filings. The years are when the filings name Michael Kelly in the role, so the role may have started earlier or lasted longer.
PI
Prime Medicine, Inc.
Director
2022 – 2026 · Public company (PRME)
NI
Neogenomics Inc.
Director
2020 – 2026 · Public company (NEO)
DI
DMC Global Inc.
Director
2020 – 2026 · Public company (BOOM)
AI
Amicus Therapeutics, Inc.
Director
2020 – 2026 · Public company (FOLD)
HI
HOOKIPA Pharma Inc.
Director
2019 – 2022 · Public company (HOOK)
AI
Aprea Therapeutics, Inc.
Director
2020 – 2021 · Public company (APRE)
Key Colleagues at Startups
The people Michael Kelly works with at each company, as listed on that company's latest Form D.
Chroma Medicine, Inc. · Form D/A, Sep 1, 2023
BC
Bihua Chen
Director
GG
George Golumbeski
Director
KB
Kevin Bitterman
Director
BK
Brett Kaplan
Chief Financial Officer
VM
Vic Myer
Executive officer
CB
Catherine Stehman-Breen
Executive officer and director
PP
Paola Pozzi
Director
JM
Jeff Marrazzo
Director
TC
Thomas Cahill
Director